Dr Braden Higgs

Radiation Oncologist
Become a Patient

Dr Braden Higgs is dedicated to delivering compassionate and patient-centred care. His honest and engaging approach to communication ensures his patients and their loved ones are well-informed and supported throughout all stages of their journey.


Dr Braden Higgs is an experienced consultant radiation oncologist at Icon Cancer Centre Windsor Gardens. He provides treatment services at Icon Cancer Centre sites in Windsor Gardens and Noarlunga. In 2000, Braden graduated from the University of Adelaide and worked as a junior doctor in London before returning to South Australia for his specialist training. He was awarded fellowship to the Royal Australian and New Zealand College of Radiologists (FRANZCR) in 2009 and completed a clinical and research fellowship at the Royal Brisbane and Women’s Hospital in 2010. Since 2011, he has held senior radiation oncology staff specialist positions at the Royal Adelaide and Queen Elizabeth Hospitals, where he is a member of the uro-oncology, gynae-oncology and lung cancer multidisciplinary teams.

Braden contributes to research, teaching and promotion of best radiotherapeutic practice through his roles as an executive member of the RANZCR Faculty of Radiation Oncology Genito-Urinary Group (FROGG) and steering committee member of the South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC).  He has contributed to national (eviQ) treatment guidelines in prostate and gynaecological cancer.

He was the Director of Training at the Royal Adelaide Hospital from 2015-2019 and continues to lecture radiation therapy students at the University of South Australia. He is the local principal investigator of several multi-centre national and international trials in prostate and kidney cancer. Braden has previously co-convened the annual scientific meetings of both the Australasian Brachytherapy Group (ABG) and RANZCR.

Braden’s clinical experience covers a broad range of solid tumour malignancies, with a special interest in prostate cancer, bladder cancer, kidney cancer, gynaecological cancer, lung cancer and palliative radiation therapy. He uses the latest advanced technologies, including volumetric modulated arc therapy (VMAT)intensity modulated radiation therapy (IMRT)image guided radiotherapy (IGRT) and stereotactic radiation therapy (SBRT) and has additional expertise in gynaecological brachytherapy.

Affiliations & Memberships

  • Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
  • American Society for Radiation Oncology (ASTRO)
  • Executive Member, Faculty of Radiation Oncology Genito-Urinary Group (FROGG)
  • European Society for Therapeutic Radiology and Oncology (ESTRO)
  • Royal Australian and New Zealand College of Radiologists (RANZCR)
  • Steering Committee, South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC)
  • Trans Tasman Radiation Oncology Group (TROG)

Special Interests

Dr Braden Higgs accepts referrals for all cancer types, with a special clinical interest in:
  • Genitourinary cancer
  • Gynaecological cancer
  • Lung cancer
  • Palliative care
  • Prostate cancer

Icon Locations

Adelaide (Windsor Gardens) View centre
Noarlunga View centre

Visiting Locations

  • Royal Adelaide Hospital
  • The Queen Elizabeth Hospital


  • Long-Term Outcomes of TROG 13.01 SAFRON II Randomized Trial of Single- Versus Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases. S Siva, P Sakyanun, T Mai, W Wong, A Lim, J Ludbrook, C Bettington, A Rezo, D Pryor, N Hardcastle, T Kron, B Higgs, H Le, M Skala, S Gill, T Eade, R Awad, G Sasso, S Vinod, R Montgomery, D Ball, M Bressel. Journal of Clinical Oncology 2023 Jul, 41, no 19 3493-3498.

  • Patterns of practice regarding use of radiation therapy following radical prostatectomy: A survey of Radiation Oncologists and Urologists in Australia and New Zealand. Lawless A, Kneebone A, Armstrong S, Chander S, Christie D, Finnigan R, Hayden A, Higgs B, Knox M, Sasso G, Sidhom M, Shakespeare TP, Holt T. Journal of Medical Imaging and Radiation Oncology, 2023 Aug. 67(5):556-563.

  • Evaluation of Hypofractionated Radiation Therapy Use and Patient-Reported Outcomes in Men With Nonmetastatic Prostate Cancer in Australia and New Zealand. D Pryor, J Martin, J Millar, H Day, W Ong, M Skala, L FitzGerald, B Hindson, B Higgs, M O’Callaghan, F Syed, A Hayden, S Turner, N Papa. JAMA Network Open. 2021;4(11):e2129647.

  • TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney – FASTRACK II. S Siva, B Chesson, M Bressel, D Pryor, B Higgs, H Reynolds, N Hardcastle, R Montgomery, B Vanneste, V Khoo, J Ruben, E Lau, M Hofman, R De Abreu Lourenco, S Sridharan, N Brook, J Martin, N Lawrentschuk, T Kron, F Foroudi. BMC Cancer, 2018. Article number: 1030.

  • Development of quality indicators to monitor radiotherapy care for men with prostate cancer: A modified Delphi method. Tsiamis, J. Millar, S. Baxi, M. Borg, P. De Ieso, H. Elsaleh, F. Foroudi, B. Higgs, T. Holt, J. Martin, K. Moretti, D. Pryor, M. Skala & S. Evans.Radiotherapy and Oncology, 2018. 128(2): 308-314.